FibroGen (FGEN) News Today → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free FGEN Stock Alerts $1.14 +0.01 (+0.88%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFibroGen (FGEN) Scheduled to Post Quarterly Earnings on Mondayamericanbankingnews.com - May 4 at 2:36 AMFibroGen Q1 2024 Earnings Previewmsn.com - May 3 at 8:52 PMFibroGen (FGEN) Scheduled to Post Earnings on Mondaymarketbeat.com - April 30 at 1:37 PMFibroGen to Report First Quarter 2024 Financial Resultsglobenewswire.com - April 29 at 7:00 AMFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meetingfinance.yahoo.com - April 24 at 8:11 PMFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meetingglobenewswire.com - April 24 at 4:02 PMFibroGen (FGEN) Price Target Increased by 40.00% to 1.79msn.com - April 17 at 10:49 PMFibroGen, Inc. (NASDAQ:FGEN) Short Interest Updatemarketbeat.com - April 16 at 5:16 PMAnalysts Set Expectations for FibroGen, Inc.'s Q1 2025 Earnings (NASDAQ:FGEN)marketbeat.com - April 4 at 9:29 AMFibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscapemarkets.businessinsider.com - April 3 at 4:31 PMFibroGen falls after early-stage data for prostate cancer drugmsn.com - April 3 at 4:31 PMFibroGen (FGEN) Gets a Sell from Goldman Sachsmarkets.businessinsider.com - April 3 at 9:27 AMFibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancerglobenewswire.com - April 2 at 5:46 PMFibroGen to Present at 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - March 26 at 7:00 AM3 Nightmare Nasdaq Stocks Not Worth Holding Another Dayinvestorplace.com - March 20 at 3:45 PMInsider Buying: FibroGen, Inc. (NASDAQ:FGEN) CEO Buys 50,000 Shares of Stockinsidertrades.com - March 12 at 5:04 AMFibroGen, Inc. (NASDAQ:FGEN) CEO Thane Wettig Buys 50,000 Sharesmarketbeat.com - March 11 at 7:47 PMFibroGen, Inc.: FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officerfinanznachrichten.de - March 11 at 10:13 AMFibroGen Appoints Deyaa Adib As CMOmarkets.businessinsider.com - March 11 at 10:13 AMFibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officerglobenewswire.com - March 11 at 7:00 AMArmistice Capital LLC Purchases 3,536,000 Shares of FibroGen, Inc. (NASDAQ:FGEN)marketbeat.com - March 3 at 10:50 AMWilliam Blair Weighs in on FibroGen, Inc.'s Q2 2024 Earnings (NASDAQ:FGEN)marketbeat.com - February 29 at 8:38 AMUS$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Resultsfinance.yahoo.com - February 29 at 8:20 AMFibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 29 at 8:20 AMFibroGen Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - February 28 at 7:17 AMAcadian Asset Management LLC Purchases Shares of 1,615,094 FibroGen, Inc. (NASDAQ:FGEN)marketbeat.com - February 28 at 5:45 AMFibroGen, Inc.: FibroGen Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - February 27 at 9:44 AMFibroGen (NASDAQ:FGEN) Rating Reiterated by William Blairmarketbeat.com - February 27 at 9:33 AMFibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023finance.yahoo.com - February 26 at 7:33 PMFibroGen regains rights to anemia drug from AstraZenecareuters.com - February 26 at 4:18 PMFibroGen Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 26 at 4:06 PMFibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Koreaglobenewswire.com - February 26 at 4:05 PMPrimecap Management Co. CA Has $12.71 Million Stake in FibroGen, Inc. (NASDAQ:FGEN)marketbeat.com - February 26 at 8:56 AMHere's what Wall Street expects from FibroGen's earnings reportmarkets.businessinsider.com - February 25 at 9:18 AMFGEN Jan 2026 1.000 callfinance.yahoo.com - February 24 at 1:52 PMFibroGen's Earnings Outlookbenzinga.com - February 23 at 2:53 PMFibroGen Stock (NASDAQ:FGEN) Insider Tradesbenzinga.com - February 21 at 7:27 PMFirst Gen Corp FGENmorningstar.com - February 21 at 2:26 PMFibroGen (FGEN) Set to Announce Earnings on Mondaymarketbeat.com - February 21 at 8:58 AMFGEN Jan 2025 3.500 callfinance.yahoo.com - February 20 at 1:31 PMFibroGen to Report Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 20 at 8:31 AMFibroGen to Report Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 20 at 7:00 AMFGEN Jan 2025 2.500 putfinance.yahoo.com - February 17 at 9:30 AMFGEN Mar 2024 2.000 callfinance.yahoo.com - February 17 at 12:28 AMSell Rating on FibroGen Amid Skepticism Over Clinical Outcomes and Drug Efficacymarkets.businessinsider.com - February 15 at 3:32 PMFibroGen, Inc. (NASDAQ:FGEN) Given Consensus Rating of "Reduce" by Analystsmarketbeat.com - February 13 at 1:58 AMFGEN Jan 2025 3.500 putca.finance.yahoo.com - February 10 at 8:54 PMFibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024finance.yahoo.com - February 5 at 10:11 AMFibroGen, Inc. (NASDAQ:FGEN) Shares Acquired by Assenagon Asset Management S.A.marketbeat.com - February 4 at 5:03 AMFibroGen Target of Unusually High Options Trading (NASDAQ:FGEN)marketbeat.com - January 30 at 1:36 PM Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address The asset beating inflation by 4x (Ad)"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties. That's why we have released our Free Precious Metals Investment Guide that explains all the details FGEN Media Mentions By Week FGEN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FGEN News Sentiment▼0.000.42▲Average Medical News Sentiment FGEN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FGEN Articles This Week▼42▲FGEN Articles Average Week Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Eliem Therapeutics News Today Clearside Biomedical News Today OptiNose News Today Barinthus Biotherapeutics News Today Cartesian Therapeutics News Today Cellectar Biosciences News Today Immunic News Today Vaccitech News Today Anixa Biosciences News Today CytomX Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FGEN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityAutomatic Income (from home)Awesomely, LLCThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
